期刊文献+

应城市11455例HPV基因分型筛查宫颈病变临床价值研究 被引量:2

下载PDF
导出
摘要 宫颈癌是最常见的妇科恶性肿瘤之一,其发病率仅次于乳腺癌,是目前唯一一个明确了病因的恶性肿瘤[1],且发病年龄逐渐下降,发病率和病死率逐年上升。宫颈上皮内瘤变(cervical intraepithelial neoplasias,CIN)是宫颈浸润癌的癌前病变,人乳头瘤病毒(human papillomavirus,HPV)主要侵犯人生殖道,诱发生殖道疾病。根据致病力和危险性大小,HPV分为低危型和高危型,其中,低危型多引起肛门、尿道口等部位尖锐湿疣及低度CINI,而多项研究显示,持续的高危型人乳头瘤病毒(high risk human papillomavirus,hr-HPV)感染是宫颈癌及其癌前病变的主要病因[2]。
作者 彭琪彦
出处 《中国实验诊断学》 2020年第10期1665-1667,共3页 Chinese Journal of Laboratory Diagnosis
  • 相关文献

参考文献8

二级参考文献73

  • 1Kirby T. FDA approves new upgraded Gardasil 9[J]. Lancet Oncol, 2015,16(2) :e56.
  • 2Pagliusi SR, Aguado MT. Efficacy and other milestones for human papillomavirus vaccine introduction [J]. Vaccine,2004,23 (5) : 569-578.
  • 3Paavonen J. Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types6/11/16/18) vaccine clinical trials[J]. Curr Med Res Opin, 2008,24 (6) : 1623- 1634.
  • 4Szarewski A,Poppe WA,Skinner SR,et al. Efficacy of the human papillomavirus(HPV) -16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV- 16/18[J]. Int J Cancer, 2012,131 ( 1 ) : 106-116.
  • 5Roteli-Martins CM,Naud P,De Borba P,et al. Sustained immunogenicity and efficacy of the HPV- 16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up[J]. Hum Vaccin Immunother, 2012,8(3 ) : 390-397.
  • 6Kjaer SK,Sigurdsson K,Iversen OE,et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions[J]. Cancer Prev Res,2009,2 (10) :868-878.
  • 7FUTURE I / ]1 Study Group,Dillner J, Kjaer SK,et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial[J]. BMJ,2010,341 : c3493.
  • 8Castellsagu6 X,Mufioz N,Pitisuttithum P,et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age [J]. Br J Cancer, 2011,105 ( 1 ) : 28-37.
  • 9Carter JR, Ding Z, Rose BR. HPV infection and cervical disease: areview[J]. Aust N Z J Obstet Gynaecol, 2011,51 ( 2 ) : 103-108.
  • 10Olsson SE,Kjaer SK,Sigurdsson K,et ai. Evaluation of quadrivalent HPV6/I 1/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection[J[. Hum Vacc, in, 2009,5 (10) :696- 704.

共引文献73

同被引文献23

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部